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longitudinal studies on the natural history of anal, penile, and oropharyngeal cancers.
The objective of this paper is the synthesis of the totality of evidence on anal, penile, 
and oropharyngeal cancers for the purpose of parameterizing decision analytic 
modeling. Following the known natural history of cervical carcinogenesis, our goal is 
to estimate the rates of transition from HPV infection to precancer, the rate of 
precancer clearance, and the rate of progression of precancer to cancer. METHODS:
We conducted a systematic review of the literature to identify all articles with longitu-
dinal data on the natural history of anal, penile, and oropharyngeal cancers. Including 
those studies that report quantiﬁ able evidence, we conduct a meta-analysis on the 
core parameters. The review was performed as per the methods recommended by 
the Cochrane Collaboration. RESULTS: Using PubMed, we identiﬁ ed 605 articles rel-
evant to the anal site, 540 articles for the penile site, and 267 on the oropharyngeal 
site. However, systematic review resulted in only 9 studies, all of which pertained to
anal precancer/cancer. Given the available data, we estimated the annual rates of pre-
cancer clearance and progression to be 11.4% (8.34%, 14.55%) and 2.18% (0.92%, 
3.47%), respectively. CONCLUSIONS: Decision analytic models provide a frame-
work for formulation of vaccination policies, incorporating all available evidence. This
review summarizes the totality of evidence on HPV and these three cancers to inform
health policy, speciﬁ cally policies concerning male vaccination against papillomavirus
(MVP).
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OBJECTIVES: Medical treatment for mRCC during 2002 represented around 4% of 
the resources designed for cancer treatment in Colombia; a local study has shown that
Sunitinib (SU) was the most cost-effective medication for ﬁ rst-line treatment of mRCC. 
We evaluated the budgetary impact of including SU as choice for ﬁ rst-line treatment
of mRCC compared to the current treatment being offered in Colombia (Interferon-á
(IFN), BevacizumabIFN and Sorafenib). METHODS: Sunitinib’s budgetary impact 
was estimated including mRCC patients which were candidates to receive ﬁ rst-line 
treatment under the SGSSS, using a 5-year time horizon. A Markov model was devel-
oped to predict costs simulating disease progression. Data regarding frequency of use
and health service cost units consumed was taken from a series of 24 patients treated
in four different cities. Service costs corresponded to the average value billed by the 
HMOs, calculated from 33 sources of information which were representative of the
country’s market. The 5-year projected proﬁ le for the current treatment of patients
suffering from mRCC was estimated starting from each medication’s market share 
and then compared to a scenario of changing Sunitinib’s share to being 100%. The
measures of effectiveness applicable for the projection were taken from previously-
published clinical trials. A One-way sensitivity analysis was conducted for validating
the model’s robustness and costs are shown in Colombian pesos (Col$) (Exchange rate 
1 USD  1966.26 Col$). RESULTS: The total budgetary impact of SU as ﬁ rst-line
treatment for mRCC represented a saving for the Colombian SGSSS of Col$
2,038,197,489 during 2009, Col$ 2,215,421,548 in 2010, Col$ 2,068,559,499 in 
2011, Col$ 1,923,678,137 in 2012 and Col$ 1,840,110,375 in 2013. This would 
represent an overall saving of Col$ 10,085,967,048 for the next 5-years. CONCLU-
SIONS: Including SU as the option of choice for ﬁ rst-line treatment of mRCC in the 
Colombian SGSSS would be favorable and cost-saving.
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OBJECTIVES: To assess the current literature on the cost-effectiveness of HPV DNA 
testing (HPVt) a) as an alternative to conventional cytology and b) to triage equivocal
cytology results. METHODS: Studies are included if they provide cost-effectiveness 
ﬁ gures for HPVt in relation to no screening or conventional cytology, are in English, 
based on a sample drawn from a developed market economy and were published after
2002. RESULTS: Eleven articles matching the search criterion were found. Though
time horizons and costs that are included vary, HPVt is generally found to be cost-
effective for older women. Based on a ﬁ ve year screening interval, using HPV DNA 
testing to triage atypical squamous cells of undetermined signiﬁ cance is estimated to
cost between about $2,900 to $33,000 per life year saved. CONCLUSIONS: HPVt 
may be a cost-effective screening tool for cervical cancer.
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OBJECTIVES: In current era the costs of the health keeping are increasing, therefore
the pharmacoeconomic has determing role. Analysis includes all stages of health 
keeping , but spotlights are drug costs. Selection of drugs according general criteria 
helps to save public ﬁ nance and allows it better utilization. METHODS: Valuation of 
utilization of drugs in oncological practice is based on data from the State Institute 
for Drug Control in Slovakia which have been evaluated for time period 10 years.
Data from the Public Health Insurance, which consist of drug costs, costs on diagnostic 
and therapy of oncological diseases, are attached to the former data. RESULTS: Public 
Health Insurance invested €0.19 mld on the therapy of the patients with oncological 
disease, which presented 10% from all costs on health keeping. Drugs represented
about 38% , hospitalization represented 28%, costs of diagnostic represented 15%
and ambulation health keeping represented 14%. But costs on ambulation health 
keeping have increased more than 28%, drug costs more than 15% and diagnostic 
costs more than 13%. According these data the most expensive diagnosis are breast 
cancer, colorectal cancer and the cancer of lungs. CONCLUSIONS: Health Insurances 
as ﬁ nancial institutions play the most important role in payment of complex therapy
of oncological patients. Because of new technology on diagnostic and therapy in 
oncology, economic value of costs is increasing. Costs of modern oncological therapy 
per one patient are more than approximately €1000.
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OBJECTIVES: There is a group of neoplasia that secretes vasoactive peptides causing
carcinoid syndrome. Surgical treatment is the election, however, if after surgery a
residual tumor is maintained, the use of somatostatin analogs: lanreotide Autogel y 
octreotide, is the treatment to follow. The objective of this research paper is to evaluate
which of the somatostatin analogs is the most effective in the symptomatic control of 
carcinoid syndrome, associated with the lowest cost. METHODS: Cost minimization
analysis from an institutional perspective was estimated, considering only direct
medical costs for a one year temporary horizon, using a decision tree model. Univariate 
sensitivity and probability analysis was carried out for this purpose. Costs were esti-
mated using prices of 2008 and are expressed in US dollars (exchange rate of 11.14
pesos/ 1 US dollar). RESULTS: According to the model, 41.3% of patients would
achieve control of their symptomatology either with Lanreotide Autogel, as with
octreotide, when adjusting the reported efﬁ cacy in the literature by the survival rate 
of one year for this illness. Treatment with Lanreotide Autogel implies the lowest 
average cost per patient with carcinoid syndrome: $15,317.18 followed by the treat-
ment with octreotide with a cost of $19,231.42. Sensitivity analyses show that lan-
reotide would support the treatment with the lowest cost, which would make it the 
dominant treatment or at least the treatment above the efﬁ ciency line. CONCLU-
SIONS: Lanreotide Autogel is the treatment that minimizes attention cost of carci-
noid syndrome, from the institutional perspective within the Mexican context.
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OBJECTIVES: Metastatic Renal cell carcinoma (mRCC), the most prevalent kidney 
cancer, is a rare malignancy with a poor prognosis; fewer than 10% of patients with 
metastatic disease survive beyond 5 years. The purpose of the study was to model the
economic and health consequences of ﬁ rst-line treatments in adult patients with mRCC 
in stages III and IV from an institutional perspective. METHODS: A cost-effectiveness 
analysis was developed using a stochastic Markov modeling approach. The model 
simulates treatment costs, progression free-months (PFM) and overall survival (OS) 
in a three-year period among four possible health states (no new progression, death 
due to mRCC, history of new progression and death due to other causes). The model 
compared in a six-week cycles: sunitinib 50 mg/day vs. sorafenib, bevacizumabIFN-
alpha and IFN-alpha alone (baseline). Transition probabilities were obtained from 
previously published trials. Resource use and costs data were obtained from random-
ized hospital records at Hospital de Oncologia CMN “Siglo XXI” in Mexico City 
(n  35). Both costs and effectiveness were discounted using a 3% annual rate. One-
way and probabilistic sensitivity analyses were performed and acceptability curves 
were constructed. RESULTS: First-line treatment with sunitinib showed the highest 
PFM and OS (10.1 and 19.9 months) followed by bevacizumabIFN-alpha (9.4 and 
19.1 months); sorafenib(5.1 and 17.3 months) and IFN-alpha alone(4.72 and 16.35 
months). Expected health care costs for sunitinib in the three-year follow-up period 
resulted in US$49,181; bevacizumabIFN-alpha (US$95,363); sorafenib (US$50,265) 
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and IFN-alpha alone (US$29,000). The ICER’s per PFM and OS resulted in US$3767.0 
and US$5668.8 (sunitinib vs. IFN-alpha alone). Results were robust to second-order
Monte Carlo sensitivity analysis (10,000 iterations). Acceptability curves showed that 
sunitinib would be a cost-saving strategy against sorafenib and bevacizumabIFN-
alpha with a probability over 70%(p  0.05). CONCLUSIONS: Results show that
sunitinib as ﬁ rst-line treatment is a cost-effective alternative among the new agents for
patients with mRCC.
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OBJECTIVES: There exists a lack of studies for cost-effectiveness analysis on treating
hepatocellular carcinoma (HCC). This study aimed at estimating life expectancy (LE), 
lifetime costs, and incremental cost-effective ratios (ICER) for ﬁ ve different treatments 
of HCC, using a semiparametric method. METHODS: A retrospective cohort study
was performed of a 1,000,000-person random sample obtained from Taiwan’s
National Health Insurance (NHI) reimbursement database. A total of 1932 newly-
diagnosed patients with HCC were indentiﬁ ed and veriﬁ ed with independent ﬁ le of 
catastrophic illnesses. These patients were followed from 1997 to 2003 with longitu-
dinal claim data, including all orders and costs of inpatient services, outpatient ser-
vices, and prescriptions dispensed at pharmacies. They were further stratiﬁ ed to ﬁ ve 
subgroups with different treatments, comprised of surgery, percutaneous ethanol injec-
tion (PEI), transarterial chemoembolization (TACE), chemotherapy and radiotherapy, 
and supportive care. The lifetime survival (up to 50 years) was estimated using the 
Monte Carlo method as well as borrowing information from the general population.
The lifetime costs were estimated by integrating the lifetime survival function and cost
function with some assumptions after the follow-up limit. The ICER was also calcu-
lated as the net cost of four different treatments study groups divided by the increased
number of life years, compared with the supportive care. RESULTS: The LE on overall 
HCC patient was 35.73 months. The surgery group had the longest LE (85.73 
months), and the supportive care group had the shortest LE (15.97 months). The 
surgery was the most cost-effectiveness treatment, which the ICER was 2358 USD per
life year (LY) after lifetime follow-up. The PEI (7124 USD/LY) was more cost-effective 
than TACE (7767 USD/LY). CONCLUSIONS: The study applied semiparametric 
method to project lifetime survival and lifetime costs, using the real cost data through 
national longitudinal reimbursement database, which might be an alternative method 
with retrospective approach on cost-effectiveness analysis.
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OBJECTIVES: To estimate the incremental cost-effectiveness of bortezomib (BTZ)
compared with lenalidomide plus dexamethasone (LENDEX) and dexamethasone 
(DEX) for the treatment of relapsed/refractory multiple myeloma in Sweden.
METHODS: We constructed a model, using Microsoft Ofﬁ ce Excel 2003 and VBA
6.3 software, to compare the BTZ, LENDEX and DEX regimens for relapsed/refrac-
tory multiple myeloma. The effects of treatment on time to progression and overall 
survival (OS) were obtained from published reports of the APEX, MM-009 and MM-
010 randomized clinical trials. Costs include drug and administration costs, adverse 
events, treatment of relapses, and end-of-life costs. Utility estimates are derived from
the literature. The analytic framework is based on ‘partitioned survival analysis’ that
allows survival data to be decomposed into three states: 1) alive before disease progres-
sion; 2) alive after progression, and; 3) dead. By computing the amount of time a 
patient is projected to spend in each state, the model estimates mean OS, quality-
adjusted life-years (QALYs), costs and cost per QALY over a 30-year time horizon, 
and performs both 1-way and probabilistic sensitivity analyses. RESULTS: BTZ mean
OS is 38.6 months compared to 24.5 and 37.8 months for DEX and LENDEX 
respectively. Mean lifetime direct medical costs per patient are approximately SEK 
562,000, 1,064,000 and 1,641,000 for DEX, BTZ and LENDEX respectively. Mean
incremental cost per QALY of BTZ compared to DEX is SEK 618,000; 95th percentile 
(424,000, 877,000) and is dominant with respect to LENDEX. The two most inﬂ u-
ential variables in our model are (1) utility prior to relapse, and (2) cost of BTZ che-
motherapy. CONCLUSIONS: BTZ and LENDEX are projected to prolong survival
relative to DEX. From a Swedish perspective, BTZ is cost-effective compared to both
DEX and LENDEX, and the incremental cost per QALY is below the threshold set 
by the World Health Organization.
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OBJECTIVES: In Canada, colorectal cancer (CRC) screening is recommended for
average-risk individuals age 50–75. A variety of options are available for screening
those at average risk for CRC, including stool-based tests (such as fecal occult blood 
test (FOBT), fecal immunochemical tests (FITs), and fecal DNA), radiological studies 
(such as Computed tomographic colonography (CTC)) and colonoscopy. Each modal-
ity differs in terms of test performance characteristics, invasiveness, safety and costs.
The objective of this study is to perform an economic evaluation of CRC screening 
considering all of the available CRC screening modalities using a Canadian perspective.
METHODS: Using decision analysis, to compare CRC screening by FIT, fecal DNA, 
CTC and the most widely utilized CRC screening strategies (FOBT and colonoscopy) 
with no screening in average risk Canadians aged 50 to 74. Outcomes included the
number of colonoscopies required, cancers, death from cancer, cost and cost per
quality-adjusted life year (QALY) gained. Model inputs were obtained from the litera-
ture and a meta-analysis of adenoma prevalence. A lifetime horizon and 5% discount-
ing was used in the analysis. All costs are reported in Canadian dollars and were inﬂ ated 
to 2007. RESULTS: In a hypothetical 100,000 patient cohort, we determined that all 
strategies (FOBT, fecal DNA, CTC, and colonoscopy) were associated with worse clini-
cal outcomes and higher costs than FIT, and thus were “dominated” by FIT. Compared
with no screening, FIT was associated with a cost per QALY gained of $3410. This
result was robust to plausible changes in known parameters. CONCLUSIONS: CRC 
screening appears cost-effective by conventional standards in comparison to the most 
common management of average risk Canadians (no screening). Although some uncer-
tainty exists as to the optimal screening strategy, FIT appears to be the optimal strategy
if the primary goal is to minimize the cost at which QALYs are purchased.
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OBJECTIVES: The US Oncology Adjuvant Trial 9735 has demonstrated an overall
survival (OS) beneﬁ t over 7 years for docetaxel plus cyclophosphamide (TC) compared 
with doxorubicin plus cyclophosphamide (AC) as adjuvant treatment for women with 
operable stage I-III invasive breast cancer. However, the cost of the TC regimen is much
higher than AC. The objective of this analysis was to evaluate the cost-effectiveness
of TC vs. AC from the perspective of the US payers. METHODS: A lifetime decision 
model with 3% discount rate was developed to estimate incremental cost (IC) per life-
year (LY) gained and IC per quality-adjusted life-year (QALY) gained. The OS beneﬁ t
of TC compared with AC over the 7-year trial period was extrapolated to lifetime using 
life expectancy of age-matched women in the general US population. Chemotherapy 
drug costs were calculated using standard dosage schedule combined with the US 
average sale price  6%. Cost associated with chemotherapy administration, and treat-
ments per episode of recurrence and adverse events were estimated from retrospective 
analyses using US claims databases. Parameter uncertainties were assessed using one-
way sensitivity analyses. RESULTS: The projected per person LYs and QALYs gained 
for TC compared with AC were 0.850 and 0.674, respectively. The estimated IC per 
person was $5325. The IC per LY and QALY gained per person were $6261 and $7905, 
respectively. The results were robust across a wide range of sensitivity analyses; in 
particular, the IC per LY and QALY gained remained under $50,000 when the duration
of the analysis was limited to 7 years. CONCLUSIONS: This analysis shows that use 
of the TC regimen compared to the standard AC regimen in patients with operable 
stage I-III breast cancer is a cost-effective treatment strategy.
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OBJECTIVES: To estimate the long-term health economic outcomes for patients 
treated with either bevacizumab added to chemotherapy or chemotherapy alone, as 
adjuvant treatment for patients with triple-negative breast cancer (TNBC). METHODS:
We used a three-state Markov Model (Disease-Free Survival (DFS), Progressed, Death)
to estimate the impact of adding one year of adjuvant treatment with bevacizumab to
an established chemotherapy regimen. The probability of disease recurrence was 
derived from a prospective clinical database analysis of 255 patients with early TNBC.
The treatment effect of bevacizumab was incorporated by applying a relative risk
reduction to the underlying risk of disease recurrence, using the expected hazard ratio 
(0.75), from the statistical power calculations of the on-going phase III BEATRICE 
study; a trial recruiting solely patients with early TNBC. Total direct medical costs
and quality-adjusted life expectancy (QALYs) were projected over patient lifetimes
from the perspective of the UK NHS. Clinical and economic outcomes were discounted
at 3.5% per annum. Probabilistic and univariate sensitivity analyses were performed.
RESULTS: Mean discounted quality-adjusted life expectancy was projected to increase 
by 0.83 QALYs following the addition of bevacizumab to chemotherapy versus che-
motherapy alone (11.35 vs 10.53 QALYs). Over patient lifetimes, discounted total
direct costs were estimated to be higher with bevacizumab, primarily attributed to 
higher pharmacy costs and the increased time spent in DFS. These results corresponded
to an incremental cost-effectiveness ratio of a43,804/QALY gained. Sensitivity analysis 
indicated results were most sensitive to the duration of the treatment effect of bevaci-
zumab and patients’ baseline characteristics (height and weight). CONCLUSIONS:
